Статья

Bladder cancer: What's new in 2019-2020

O. Karyakin,
2021

This review aims to summarize the latest data on the treatment of bladder cancer published during the specified period. Most of them are evidence-based and were obtained in randomized trials. A new classification based on molecular data was proposed at a consensus meeting of pathologists. A significant correlation has been demonstrated between life expectancy and morphological structure of the tumor. This article covers chemotherapy regimens for patient with BCG (Bacillus Calmette-Guérin) intolerance. Immunotherapeutic agents for muscleinvasive bladder cancer are being actively studied now; scientists are searching for the best treatment regimens with these drugs and their combinations with other antitumor agents. The European Association of Urology has developed a new classification of intraoperative adverse events and recommendations for pharmacotherapy and surgical treatment of patients with bladder cancer during the COVID-19 pandemic. In conclusion, the opinions of experts from the consensus meeting on the treatment of various forms of bladder cancer are given. © 2020 ABC-press Publishing House. All rights reserved.

Цитирование

Похожие публикации

Документы

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • O. Karyakin
    A.F. Tsyb Medical Radiological Research Center, Branch of the National Medical Research Radiological Center, Ministry of Health of Russia, 4 Koroleva St., Obninsk, 249031, Russian Federation
Название журнала
  • Onkourologiya
Том
  • 16
Выпуск
  • 4
Страницы
  • 147-154
Издатель
  • ABC-press Publishing House
Тип документа
  • Review
Тип лицензии Creative Commons
  • CC
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus